Compare Synopsys, Inc. (SNPS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Synopsys, Inc. trades at $505.89 (market cap $95.39B), while State Street SPDR S&P Biotech ETF trades at $152.22 (market cap $10.11B). The key difference: Synopsys, Inc. is far larger — about 9.4× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 3,374,903). Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SNPS | XBI | |
|---|---|---|
Market Cap | $95.39B | $10.11B |
Volume | 3,374,903 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $534.56 | $169.55 |
52-Week Low | $367.70 | $104.99 |
Typical Hold Time | 71 Days | 37 Days |
Enterprise Value | $102.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights AI-driven partnerships with OpenAI and Amazon, boosting growth prospects. Valuation ratios are elevated, with a P/E of 86.87, reflecting high growth expectations. Analyst sentiment is overwhelmingly positive, with a consensus price target of $572.54.
The outlook for SNPS is favorable, driven by AI integration and strategic acquisitions, but risks include high valuation sensitivity and competitive pressures. Revenue growth and margin expansion from new deals present opportunities, though investors should monitor execution risks and market volatility. The stock's proximity to key resistance levels suggests potential for near-term consolidation or breakout.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
